Begin to understand the impact of psychedelics through our reports. Covering them from different topics (e.g. depression), compounds (e.g. LSD), and countries (e.g. Switzerland), we will help you understand and take action in this fast-changing landscape.
The reports featured here are freely available and supported by our generous collaborators, sponsors, and readers. To download a shareable pdf version of the reports, you will need to make an account or log in.
OCD affects an estimated 1-2% of the population and is ranked as one of the 10 most disabling illnesses in terms of lost income and decreased quality of life in tandem with medications like SSRIs is the most common treatment. Phase I studies using psilocybin to treat OCD are underway.
Mescaline is famously derived from the San Pedro and Peyote cactic. Its healing properties have been known by Indigenous communities in the Americas for thousands of years. This compound is yet to undergo rigorous clincial studies.
DMT is a powerful yet short-lived hallucinogenic drug that naturally occurs in many plants and animals. It is the main psychoative component of the ayahuasca brew. Some research is underway with this compound.
2C-X is the name for a group of psychedelic compounds synthesized by Alexander Shulgin. The most common these compounds are 2C-B and 2C-I however, clinical evidence for their therapuetic potential is lacking.
The use of psilocybin predates written history. Its therapeutic potential is not going unnoticed as clinical trials have yielded promising results. Movements to decriminalize psilocybin are well underway in the U.S and further afield.
Known as 'ecstasy' and 'molly,' MDMA is showing serious theraputic potential for the treatment of PTSD and other mental disorders. Clinical trials are in Phase III and many believe MDMA could by FDA approved by 2023.
Ibogaine is found in several plants native to Western Africa and has a long history of traditional use. Now, researchers are investigating the effectivness of using ibogaine to treat substance use disorders.
There is estimated to be over 150 million people living with some form of substance use disorders worldwide. Thankfully, clinical trials are taking place all over the world using psychedelics like psilocybin, MDMA, ayahuasca, ketamine and ibogaine to treat these disorders and are producing positive results.
Psychedelics have a long history and have been used for centuries. The knowledge that is possessed by indigenous communities and how they should be compensated is currently a hot topic in psychedelics.
It is estimated that chronic pain affects at least 30 per cent of the world’s population. The fallout from the Opioid Epidemic has spurred a new interested in finding more effective treatments for pain management. Some trials using psychedelics like psilocybin to treat phantom-limb pain and cluster headaches are underway.
Anxiety impacts 300 million people. Psychedelics show promise in alleviating symptoms of anxiety. Studies over the last 20 years with LSD, MDMA, ketamine and more psychedelics are paving the way towards psychedelic-assisted therapy for anxiety.
Autism spectrum disorders are believed to affect 1 in 160 children globally. At present, there are no FDA-approved treatments for autistic adults. There has been little research to date regarding the use of psychedelics to treat autism spectrum disorders, however, one trial using MDMA yielded promising results.
At the simplest level, personality entails the characteristic patterns of thoughts, feelings and behaviours that make a person unique. Personality is ever-changing and it is believed that psychedelics have the ability to influence these changes.
Nearly 4% of the world's population is affected by one of more than 80 different autoimmune diseases. Many of these diseases have no cure. Researchers believe that psychedelics have anti-inflammatory properties which may be used to treat these disorders.
The two most common eating disorders are anorexia nervosa and bulimia nervosa, affecting roughly 16 million people globally. Current medications have limited success in treating people with these disorders. Research with psychedelics including MDMA and psilocybin to treat these disorders is underway.
Healthy subjects or health normals is a term used for those who are currently not suffering from a mental health or substance use disorder. In psychedelic research, the term is often used to describe participants in Phase I or Phase II studies who are testing the safety of a treatment.
Safety is of the utmost importance when discussing any sort of drug. Not only do scientists have to prove drugs are therapeutically effective, but they must also ensure drugs are safe for human consumption.
Microdosing is the practice of regularly using low doses of psychedelic drugs. This relatively recent phenomenon was made popular through the anecdotal reports of young professionals from all walks of life, taking sub-hallucinogenic doses of psychedelics for a variety of reasons.
About 30% or one in three of those suffering from depression are dealing with so-called treatment-resistant depression (TRD). The name refers to that these patients have tried at least two treatment options, without success. Psychedelics may offer hope to those suffering from TRD.
More than 700,000 people die by suicide each year. Suicidality is often linked to a range of mental health disorders including depression and substance use disorders. Ketamine is showing great promise to rapidly alleviate suicidal thoughts, something which is very important when we think of the outcome.
PTSD is generally grouped alongside anxiety disorders given the similar symptomology that is experienced. There is estimated to be over 300 million people living with PTSD globally. MDMA holds significant promise for treating PTSD and is in Phase III of the clinical trial process,
There is estimated to be 45 million people living with some form of bipolar disorder across the globe. No trials have taken place using psychedelics to treat bipolar disorders as researchers are unsure if psychedelics may induce a manic episode in participants.
Can psychedelics aid in creative pursuits? And if they can, how do they help? Creativity and psychedelics have long been a topic of discussion and some research is pointing out how they are intertwined.
Schizophrenia and psychedelics have a long and intertwined history. First psychiatrists took LSD to better understand their patients as they believed that the acute LSD experience mirrored that of their patients. This perspective, of psychedelics as so-called psycho-mimetics persisted for a long time in academia and in the common understanding. Little research has been done on how psychedelics can help those with schizophrenia.
Reports on Psychedelic: From Addiction to Placebo, and from Anxiety to United States
Psychedelics are becoming serious contenders for the next generation of medicines for mental health. They are being taken through clinical trials, and investment is pouring in on several continents. Our reports cover psychedelics from a variety of angles.
First, we cover them per topic, with a focus on the different mental health disorders for which they can be useful. Second, we investigate the individual compounds and how they are being applied. Third, we inspect the leading countries and report on where they stand with regard to the implementation of psychedelics.
Become a psychedelic insider!
With a free Blossom membership you will always be in the know.
📰 Weekly newsletter about the psychedelic research
✔️ Unlimited access to our database and original articles